米氮平与帕罗西汀治疗抑郁症对照研究

A control study of mirtazapine vs.paroxetine in the treatment of depression

目的评价米氮平与帕罗西汀治疗抑郁症的疗效与安全性。方法将64例抑郁症住院患者和门诊患者随机分为两组,分别给予米氮平和帕罗西汀治疗,疗程6w。于治疗前和治疗第1w、2w、4w、6w末采用汉密顿抑郁量表、汉密顿焦虑量表、临床疗效总评量表和副反应量表评定临床疗效和不良反应。结果两组治疗各时段汉密顿抑郁量表、汉密顿焦虑量表评分均显著下降;米氮平组显效时间较帕罗西汀组快,药物不良反应明显少于帕罗西汀组,且米氮平很少引起性功能障碍。结论米氮平是一种安全、有效的新一代抗抑郁药,依从性好,安全性高。

Objective To evaluate the curative effects and safety of mirtazapine vs. paroxetine in the treatment of depression. Methods 64 inpatients and outpatients with depression were randomly divided into mirtazapine and paroxetine groups （ both n = 32） for 6 weeks. Curative effects were assessed with the Hamilton Depression Scale（HAMD）, the Hamilton Anxiety Scale（HAMA） and the Clinical Global Impression （CGI）, and side reactions with the Treatment Emergent Symptoms Scale（TESS） before treatment and at the ends of the 1 st, 2 nd, 4 th and 6th week treatment. Results At each chron-stage, scores of the HAMD and HAMA in both groups decreased significantly; mirtazapine took effects faster than did, its adverse reactions were fewer than the paroxetine＇s and it seldom caused sexual disturbance. Conclusion Mirtazapine is an effective and safe neo-antidepressant, and has better compliance and higher safety.